Last reviewed · How we verify

NCT06246773

Feasibility of a Positive Parenting Program for Women Experiencing Homelessness Who Have a History of Interpersonal Violence

Completed NA Last updated 7 April 2026
What this trial tests

NA trial testing Positive Parenting Program in Interpersonal Violence in 28 participants. Completed in 24 October 2025.

Timeline
26 March 2024
Primary endpoint
24 October 2025
24 October 2025

Quick facts

Lead sponsorThe University of Texas Health Science Center, Houston
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeother
Enrollment28
Start date26 March 2024
Primary completion24 October 2025
Estimated completion24 October 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

The University of Texas Health Science Center, Houston

Who can join

16 and older, female only, with Interpersonal Violence or Homelessness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to strengthen the skills and self-efficacy of women by addressing the social and emotional trauma that they have experienced from interpersonal violence (IPRV) and homelessness and to promote positive parenting strategies through Play and Learning Strategies (PALS), an evidence based intervention.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Interpersonal Violence

Currently open trials in the same condition.

Other The University of Texas Health Science Center, Houston trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06246773.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing